Introduction The pace of legal change continues to accelerate in 2026. Attorneys are navigating increased regulatory scrutiny, rapidly evolving artificial intelligence laws, and market-driven shifts...
Practical Guidance continues to evolve to meet the real-world demands of today’s legal professionals, and December 2025 delivers one of our most robust updates yet. Across practice areas, this release...
Each month, Practical Guidance expands its library with tools, templates, and practice notes designed to help legal practitioners move faster and stay aligned with evolving legal requirements. The November...
By: Neil F. Aragones , Sean Craig , Susan C. Hughes , Peter C. Miller , Rosann Torres , and Charles R. Zubrzycki , Practical Guidance The following text is a summary of the full treatise section, available...
New ADAM Program Dashboard Aims to Increase Public Awareness of Missing Children An interactive dashboard launched recently by LexisNexis Risk Solutions is designed to increase public access to information...
Copyright © 2026 LexisNexis and/or its Licensors.
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER